Technical Analysis for RLAY - Relay Therapeutics, Inc.

Grade Last Price % Change Price Change
F 7.50 -5.66% -0.45
RLAY closed down 5.66 percent on Monday, March 18, 2024, on 1.49 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
3 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
Death Cross Bearish 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Wide Bands Range Expansion 0.00%
Below Lower BB Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Volume Surge Other -5.66%
NR7 Range Contraction -5.66%

   Recent Intraday Alerts

Alert Time
Down 5% about 9 hours ago
Possible NR7 about 10 hours ago
60 Minute Opening Range Breakdown about 11 hours ago
Down 3% about 15 hours ago
Fell Below Previous Day's Low about 15 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Relay Therapeutics, Inc. Description

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Its product candidates include RLY-1971, an oral small molecule inhibitor of the protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 (SHP2) that is in Phase 1 dose escalation studies in patients with advanced or metastatic solid tumors; RLY-4008, an oral small molecule selective inhibitor of fibroblast growth factor receptor 2 (FGFR2) for patients with advanced solid tumors having oncogenic FGFR2 alterations; and RLY-PI3K1047, a lead compound that targets cancer-associated mutant variants of phosphoinositide 3-kinase alpha. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Solid Tumors Drug Discovery Enzymes Precision Medicine Tyrosine Kinase Receptors Tyrosine Kinase Advanced Solid Tumors Fibroblast Growth Factor Fibroblast Growth Factor Receptor Metastatic Solid Tumors Proto Oncogene Tyrosine Protein Kinase Src Ptpn11

Is RLAY a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 19.23
52 Week Low 5.95
Average Volume 1,084,330
200-Day Moving Average 9.96
50-Day Moving Average 9.94
20-Day Moving Average 9.74
10-Day Moving Average 9.23
Average True Range 0.62
RSI (14) 25.93
ADX 20.98
+DI 11.96
-DI 37.18
Chandelier Exit (Long, 3 ATRs) 9.31
Chandelier Exit (Short, 3 ATRs) 9.25
Upper Bollinger Bands 11.49
Lower Bollinger Band 7.99
Percent B (%b) -0.14
BandWidth 35.94
MACD Line -0.45
MACD Signal Line -0.17
MACD Histogram -0.2854
Fundamentals Value
Market Cap 955.97 Million
Num Shares 127 Million
EPS -2.67
Price-to-Earnings (P/E) Ratio -2.81
Price-to-Sales 46.66
Price-to-Book 1.49
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 8.27
Resistance 3 (R3) 8.32 8.11 8.14
Resistance 2 (R2) 8.11 7.92 8.09 8.09
Resistance 1 (R1) 7.81 7.80 7.71 7.76 8.05
Pivot Point 7.60 7.60 7.55 7.58 7.60
Support 1 (S1) 7.30 7.41 7.20 7.25 6.95
Support 2 (S2) 7.09 7.29 7.07 6.91
Support 3 (S3) 6.79 7.09 6.86
Support 4 (S4) 6.74